Alnylam Pharmaceuticals :
ALNY
ALNY
Stock Data
$458.12
$7.22 (1.55%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Alnylam Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to the development and commercialization of innovative therapeutics based on RNA interference. The company's portfolio includes treatments for rare genetic conditions, such as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, among others. Alnylam is also exploring treatments for a variety of other diseases, including hemophilia, hypercholesterolemia, and Alzheimer’s disease. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has formed strategic partnerships with several leading pharmaceutical companies to advance its mission of transforming scientific discoveries into breakthrough therapies.
All Alnylam Pharmaceuticals Articles
74 Articles